{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Graft+Failure", "query": { "condition": "Multiple Graft Failure" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Graft+Failure&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T07:38:16.806Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00447187", "title": "Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Corneal Diseases", "Cornea Transplant" ], "interventions": [ { "name": "LX201", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lux Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 368, "start_date": "2007-04", "completion_date": "2010-11", "has_results": false, "last_update_posted_date": "2012-10-11", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00447187" }, { "nct_id": "NCT03781726", "title": "Multi-center Study to Transplant Hepatitis-C Infected Kidneys", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Failure Chronic", "Hepatitis C" ], "interventions": [ { "name": "glecaprevir/pibrentasvir treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Raymond Chung", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 30, "start_date": "2019-04-10", "completion_date": "2021-12-31", "has_results": true, "last_update_posted_date": "2022-01-26", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 7, "location_summary": "Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03781726" }, { "nct_id": "NCT01135849", "title": "B-Receptor Signaling in Cardiomyopathy", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Carcinomas", "Amyloidosis", "Anal Cancer", "Anemia", "Cholangiocarcinoma of the Extrahepatic Bile Duct", "Transitional Cell Carcinoma of Bladder", "Bone Marrow Transplant Failure", "Bone Cancer", "Cancer of Brain and Nervous System", "Breast Cancer", "Carcinoma of the Large Intestine", "Endocrine Cancer", "Esophageal Cancer", "Eye Cancer", "Gall Bladder Cancer", "Gastric (Stomach) Cancer", "Gastrooesophageal Cancer", "Gastrointestinal Stromal Tumor (GIST)", "Gynecologic Cancers", "Head and Neck Cancers", "Hepatobiliary Neoplasm", "Kidney (Renal Cell) Cancer", "Leukemia", "Lung Cancer", "Hodgkin Disease", "Lymphoma, Non-Hodgkin", "Mesothelioma", "Multiple Myeloma", "Myelodysplastic Syndromes (MDS)", "Neuroendocrine Tumors", "Myeloproliferative Disorders", "Pancreatic Cancer", "Prostate Cancer", "Skin Cancer", "Soft Tissue Sarcoma", "Testicular Cancer", "Thymus Cancer", "Thyroid Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Daniel Bernstein", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "40 Years", "sex": "ALL", "summary": "Up to 40 Years" }, "enrollment_count": 99, "start_date": "2008-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01135849" }, { "nct_id": "NCT00447642", "title": "Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Corneal Transplantation", "Corneal Graft Rejection" ], "interventions": [ { "name": "LX201", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Lux Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2007-04", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-10-11", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00447642" }, { "nct_id": "NCT02649946", "title": "Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Stenosis", "Restenosis" ], "interventions": [ { "name": "Covera Vascular Covered Stent following PTA", "type": "DEVICE" }, { "name": "Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon", "type": "PROCEDURE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "C. R. Bard", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 280, "start_date": "2016-06", "completion_date": "2021-02", "has_results": true, "last_update_posted_date": "2021-12-21", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 16, "location_summary": "Tempe, Arizona • Laguna Hills, California • Englewood, Colorado + 11 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02649946" }, { "nct_id": "NCT05881278", "title": "XVIVO Heart Perfusion System (XHPS) With Supplemented XVIVO Heart Solution (SXHS)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure", "Transplant; Failure, Heart" ], "interventions": [ { "name": "Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "XVIVO Perfusion", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 141, "start_date": "2023-10-10", "completion_date": "2029-11", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 20, "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 14 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05881278" }, { "nct_id": "NCT02960646", "title": "Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Aplastic Anemia", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Lymphoblastic Lymphoma", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Plasma Cell Myeloma", "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "Recurrent Hodgkin Lymphoma", "Recurrent Non-Hodgkin Lymphoma", "Recurrent Plasma Cell Myeloma", "Therapy-Related Myelodysplastic Syndrome" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Total-Body Irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE", "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2017-01-18", "completion_date": "2023-02-13", "has_results": false, "last_update_posted_date": "2023-02-16", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02960646" }, { "nct_id": "NCT00290628", "title": "Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Diamond-blackfan Anemia", "Fanconi Anemia", "Graft Versus Host Disease", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mycophenolate mofetil", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "45 Years", "sex": "ALL", "summary": "Up to 45 Years" }, "enrollment_count": 43, "start_date": "1999-10", "completion_date": "2007-04", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00290628" }, { "nct_id": "NCT00975975", "title": "Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Chronic Lymphocytic Leukemia", "Myelodysplasia", "Non-Hodgkin's Lymphoma", "Hodgkin's Disease", "Multiple Myeloma", "Myelofibrosis", "Anemia, Aplastic", "Hemoglobinuria, Paroxysmal" ], "interventions": [ { "name": "Basiliximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2009-09", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2016-02-26", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00975975" }, { "nct_id": "NCT03575910", "title": "HEARTBiT: Multi-Marker Blood Test for Acute Cardiac Transplant Rejection", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Heart Transplant Failure and Rejection", "Heart Failure", "Heart Diseases", "Heart Failure，Congestive", "Transplant; Failure, Heart", "Transplant Failure" ], "interventions": [], "intervention_types": [], "sponsor": "University of British Columbia", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 196, "start_date": "2018-08-09", "completion_date": "2026-03-30", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-06-10T07:38:16.806Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03575910" } ] }